RT Journal Article
SR Electronic
T1 Systems-level immunomonitoring from acute to recovery phase of severe COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.03.20121582
DO 10.1101/2020.06.03.20121582
A1 Rodriguez, Lucie
A1 Pekkarinen, Pirkka
A1 Lakshmikanth, Tadepally
A1 Tan, Ziyang
A1 Consiglio, Camila Rosat
A1 Pou, Christian
A1 Chen, Yang
A1 Mugabo, Constantin Habimana
A1 Quoc, Anh Nguyen
A1 Nowlan, Kirsten
A1 Strandin, Tomas
A1 Levanov, Lev
A1 Mikes, Jaromir
A1 Wang, Jun
A1 Kantele, Anu
A1 Hepojoki, Jussi
A1 Vapalahti, Olli
A1 Heinonen, Santtu
A1 Kekäläinen, Eliisa
A1 Brodin, Petter
YR 2020
UL http://medrxiv.org/content/early/2020/06/07/2020.06.03.20121582.abstract
AB The immune response to SARS-CoV2 is under intense investigation, but not fully understood att this moment. Severe disease is characterized by vigorous inflammatory responses in the lung, often with a sudden onset after 5–7 days of stable disease. Efforts to modulate this hyperinflammation and the associated acute respiratory distress syndrome, rely on the unraveling of the immune cell interactions and cytokines that drive such responses. Systems-level analyses are required to simultaneously capture all immune cell populations and the many protein mediators by which cells communicate. Since every patient analyzed will be captured at different stages of his or her infection, longitudinal monitoring of the immune response is critical. Here we report on a systems-level blood immunomonitoring study of 39 adult patients, hospitalized with severe COVID-19 and followed with up to 14 blood samples from acute to recovery phases of the disease. We describe an IFNγ – Eosinophil axis activated prior to lung hyperinflammation and changes in cell-cell coregulation during different stages of the disease. We also map an immune trajectory during recovery that is shared among patients with severe COVID-19.HIGHLIGHTS Systems-level immunomonitoring from acute to recovery in severe COVID-19An IFNγ - Eosinophil axis involved in lung hyperinflammationCell-cell coregulation differ during four disease stagesBasophils and hyperinflammation modulate humoral responsesA shared trajectory of immunological recovery in severe COVID-19Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors are grateful to private donations to Karolinska Institutet from Bure Equity AB (Stockholm, Sweden) and Af Jochnick Foundation. The study was also supported by grants from Academy of Finland to E.K. (308913) and S.H. (323499) and Helsinki University Hospital (project M7100YLIT2) to P.P as well as funding from Juho Vainio Foundation to O.V and A.K.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethics Committee of the Hospital District of Helsinki and Uusimaa (HUS/853/2020) and conducted in accordance with the Declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll raw data and code required to reproduce all figures is available freely. https://ki.box.com/s/sby0jesyu23a65cbgv51vpbzqjdmipr1